Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh brother….
Jess, we could use one of your wildly bullish pep posts right about now…
“Yep, buying auph and BTC for insurance”
LOL…
It’s not Management to blame, they have some extremely talented individuals on the team (Max in sales, and the CSO) and others. It is the price of the drug.
Down again in pre market. Too expensive for the benefit of SOC.
Zzaatt, in your attempt to spread vile here, you incorrectly used words out of context..
$14.40 to $11.50 in 30 days. Scrips are a disaster. $2 million I reckon..
$12.75 to $11.58 in 3 days. Guys, any ideas why the carnage?
Jess, that article on hedge funds interest in AUPH must be yesterday’s news, and they must have reversed course and are now selling aggressively with the price action over the last week. It better bounce at $10.
Dam, this is brutal. Breaking down bad. Fortunately, I sold calls when they were REALLY elevated. The steam is out.
That would be optimistic..
I’m baaaaaack!
‘Thar she blows!!
Leaker…
Greggors, you mean $14 where it broke down?
They are all waiting to see what the sales are for Q2. Nothing else matters. Big bio won’t make a move until they see traction. Getting on a Formulary is good, but actual uptake is what separates the winners from the losers.
I hear the Glickster is back to make sure they hit $3 million..
Cer-v, weak salesforce. Both words
If they make $2 million in sales in Q2, it should be considered a home run. In another three months, it would be considered a touchdown..
Something is wrong…
The gadfly says all is good..
“No BR, it’s not a crap shoot. Lupus world endorses it. No competition in the vicinity, sales will surely come.as there is no equal drug around. It will be years before another drug can challenge it. “
The market doesn’t appear to agree right now. But, give it time, and all that matters is what Peter Greenleaf can do..
You are welcome!
I suggest that the most appropriate terminology would have been that the options were granted to her and as such she received them.
The words "acquisition" and "disposition" are used by the OSC (SEDAR) to indicate that an individual has 'bought' or 'sold' common shares, preferred shares, debentures, or whatever.
Therefore, like BR, I first concluded from the original statement that the new Director was so excited at receiving her new Directorship that she rushed out and bought a big bag of shares on the open market.
Keep up the good work, BR!!!!
A good assessment by that poster, but it still amounts to a crap shoot. The good news is in 6 months we will know if it is a hero or zero…Almost resolved..
A must read. Unbiased assessment..
Aurinia Pharmaceuticals: Recent Sell-Off Provides A Great Entry Point https://seekingalpha.com/article/4435797-aurinia-pharmaceuticals-recent-sell-off-provides-great-entry-point
An unknown unknown..
There, I did my good deed for the day..
Trust me, NO one will touch this company until they have at LEAST 3-4 quarters of sales…. And, the SOC works, and the price tag of this is Tesla like..
“A mergers and acquisitions pro, doesn’t mean a BO is off the table at all…..she did JUST acquire 53,291 shares for 12.86 a share”
Oh Ganz, where should I start. She did not ACQUIRE 53,291 shares, she was GIVEN those shares under the terms of her employment agreement..
Zep, this new person coming on board will be a board member, and not part of the direct management team. It is a great add for Aurina to be shopped and sold..
Jess, you will like this:
Cowen:" $AUPH CONSULTANT CHECKS STRENGTHEN LT CONVICTION. Clinicians are initially using Lupkynis in second line; clinician feedback has been overwhelmingly positive; benefits vs. other options(Benlysta failures) will lead to substantial 30-40% penetration; $1B+. TP=$50+ on(M&A)"
Cowen:" $AUPH CONSULTANT CHECKS STRENGTHEN LT CONVICTION. Clinicians are initially using Lupkynis in second line; clinician feedback has been overwhelmingly positive; benefits vs. other options(Benlysta failures) will lead to substantial 30-40% penetration; $1B+. TP=$50+ on(M&A)"
— Tom Silver (@TomSilver39) June 14, 2021
Short this to $10. That is where it is going. Just ask Charlie Munger
GFs are here in droves.
This has been such a sweet ride. Still at a PE of 8 or so..
CO2 In Air Hit Highest Level in Modern History
In 2020, global emissions were cut 7%, but it didn't end up changing much..
https://www.morningbrew.com/daily/stories/2021/06/07/co2-air-hit-highest-level-modern-history
It appears the environment will unravel sooner than I expected.
Neil Solomons, MD, sits down to discuss his latest study, entitled “Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet,” which will be presented at EULAR 2021. https://www.rheumatologynetwork.com/view/neil-solomons-md-efficacy-of-voclosporin-for-treatment-of-lupus-nephritis
Jess, can you email PG and ask him to leave the sweater vest home? He has worn that to every Zoom conference call this year and is becoming a little rank…. No Ivy Leaguer here..